Qiantang Longyue (钱塘隆越) Secures RMB 100M Series B for Drug-Delivery Systems

Qiantang Longyue (杭州钱塘隆越生物科技), a Hangzhou-based biotech founded in 2021, has raised RMB 100 million in Series B funding. The round was led by 惠每资本 (Himca Capital), with participation from ZJU Qizhen Venture Capital and Bioinsight Ventures (辰元创投).

What Qiantang Longyue Does

Qiantang Longyue develops innovative pharmaceutical packaging and drug-delivery systems. Its product portfolio includes:

COP prefillable syringes
Ophthalmic and vaccine delivery devices
Medical-aesthetics injection systems
Nebulization devices
Smart electronic injector pens

The company operates an 8,000 m² GMP-compliant Class C cleanroom, with quality and R&D systems aligned to FDA, EU, and NMPA requirements. It offers drug companies one-stop custom solutions spanning design and validation through registration and commercial-scale manufacturing.

The Round at a Glance

Company: Qiantang Longyue (杭州钱塘隆越生物科技)
Headquarters: Hangzhou
Founded: 2021
Round type: Series B
Amount raised: RMB 100,000,000
Lead investor: 惠每资本 (Himca Capital)
Additional investors: ZJU Qizhen Venture Capital, Bioinsight Ventures (辰元创投)
Funding date: September 17, 2026

Why Drug-Delivery and Packaging Matter

Drug-delivery systems and pharmaceutical packaging sit at the intersection of formulation science, device engineering, and regulatory compliance. For drug developers, the delivery device is not a commodity — it affects dosing accuracy, patient experience, stability, and ultimately whether a therapy can be approved and commercialized in a given market.

Prefillable syringes, for example, are central to injectable biologics and vaccines, where container-device compatibility and extractables/leachables profiles must satisfy stringent regulatory scrutiny. COP (cyclic olefin polymer) prefillable syringes are one option in this space, offering an alternative material to traditional glass.

Qiantang Longyue's portfolio extends beyond injectables into ophthalmic and vaccine delivery, medical-aesthetics injection systems, nebulization devices, and smart electronic injector pens. That breadth suggests a platform strategy rather than a single-product play — serving multiple therapeutic and aesthetic categories with customized delivery solutions.

Manufacturing and Regulatory Infrastructure

The company's 8,000 m² GMP-compliant Class C cleanroom is a significant asset. Cleanroom classification and GMP compliance are prerequisites for supplying drug companies, and alignment with FDA, EU, and NMPA requirements positions Qiantang Longyue to support customers pursuing registration in major markets.

The one-stop model — from design and validation through registration and commercial-scale manufacturing — is designed to reduce the number of vendors a drug company must coordinate. For pharma partners, consolidating delivery-device development and manufacturing with a single qualified supplier can simplify timelines and quality management.

Acquisition-Oriented Takeaways

For strategic acquirers and investors in the pharmaceutical services and drug-delivery space, several factors stand out:

Stage and scale: A Series B of RMB 100 million indicates the company is past early validation and scaling toward commercial manufacturing capacity.
Investor syndicate: Himca Capital led the round, joined by ZJU Qizhen Venture Capital and Bioinsight Ventures (辰元创投) — a mix of healthcare-focused and university-affiliated venture capital.
Regulatory alignment: Systems aligned with FDA, EU, and NMPA requirements broaden the addressable customer base to drug developers targeting multiple regions.
Portfolio breadth: Coverage across injectables, ophthalmic, vaccine, medical aesthetics, nebulization, and smart injector pens creates multiple revenue paths and cross-selling opportunities.

What to Watch

With Series B capital in place, Qiantang Longyue is positioned to expand manufacturing capacity, advance its device portfolio, and deepen relationships with drug-company partners. For parties evaluating the drug-delivery and pharmaceutical packaging landscape, the company's combination of GMP infrastructure, multi-market regulatory alignment, and broad device portfolio makes it a name to track.

This article is based solely on the funding and company details available at the time of the announcement. No additional investors, customers, or product claims beyond those disclosed have been included.